AMIKACIDE Amikacin 125mg / mL Solution for IM/IV Injection 3mL 5's
RXDRUG-DR-XY17729
Discreet Packaging
We recognize that purchasing medications can be a deeply personal matter. To respect your privacy, we ensure that all orders are packaged discreetly, with no indication of the contents on the packaging. This means that even our couriers remain unaware of the package contents.
Furthermore, we uphold strict confidentiality standards. We guarantee that your order information will never be disclosed to any third party. Your trust is paramount to us, and we are committed to safeguarding your privacy at every step of the process. Our dedication to discretion and confidentiality is part of our unwavering commitment to you, our valued customer.
FDA-registered Products
FDA-licensed Pharmacies
Features
Brand
AmikAcide
Full Details
Dosage Strength
125 mg / mL
Drug Ingredients
- Amikacin
Drug Packaging
Solution for Injection (I.M./I.V.) 3ml x 5's
Generic Name
AMIKACIN
Dosage Form
Solution For Injection (I.M./I.V.)
Registration Number
DR-XY17729
Drug Classification
Prescription Drug (RX)
Description
Indications/Uses
For the treatment of the following infections caused by susceptible microorganisms: Bacterial septicemia including neonatal sepsis; Respiratory tract infections; Infections of the bones and joints; Intra-abdominal infections (including peritonitis); Burns and postoperative infections; Serious and complicated urinary tract infections; Initial therapy in suspected gram-negative infections.
Dosage/Direction for Use
Adult, childn & older infant 15 mg/kg/day given as a single dose or divided into 2-3 equal doses administered at equally divided intervals. Uncomplicated UTI Single dose of 500 mg daily or 250 mg bid. Newborn Loading dose: 10 mg/kg, followed by 7.5 mg/kg every 12 hr; 0-7 days, <2 kg 7.5 mg/kg every 18-24 hr for 7-10 days. Peritoneal dialysis 7.5 mg/kg. Renal impairment CrCl >80 mL/min 15 mg/kg every 24 hr, 60-80 mL/min 12 mg/kg every 24 hr, 40-60 mL/min 7.5 mg/kg every 24 hr, 30-40 mL/min 4 mg/kg every 24 hr, 20-30 mL/min 7.5 mg/kg every 48 hr, 10-20 mL/min 4 mg/kg every 48 hr, <10 mL/min 3 mg/kg every 72 hr.
Overdosage
Peritoneal dialysis or hemodialysis will help in the removal of amikacin in blood. In the newborn infant, exchange transfusion may also be considered.
Contraindications
Known hypersensitivity to amikacin and other components of this product.
History of hypersensitivity or toxic reactions to aminoglycosides.
History of hypersensitivity or toxic reactions to aminoglycosides.
Special Precautions
This product contains metabisulfite which may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.
Safety for treatment periods longer than 14 days has not been established.
Patients treated with parenteral aminoglycosides should be under close clinical observation. Amikacin sulfate injection is potentially nephrotoxic, ototoxic and neurotoxic. Avoid concurrent use of other ototoxic or nephrotoxic agents because of the potential additive effects.
Patients with preexisting tinnitus, vertigo, subclinical high-frequency hearing loss, or renal impairment and patients who are receiving high doses and/or prolonged therapy with aminoglycosides or who have received prior ototoxic drugs are especially susceptible to ototoxicity and should be carefully observed for signs of eighth cranial nerve damage during aminoglycoside therapy.
Assess kidney function by the usual methods prior to starting therapy and daily during the course of treatment. If signs of renal irritation appear, increase hydration. A reduction in dosage may be recommended if other evidence or renal dysfunction occurs such as decreased creatinine clearance, decreased urine specific gravity, and increased BUN, creatinine or oliguria. Stop the treatment if azotemia increases or if a progressive decrease in urinary output occurs.
Amikacin should be used with caution in patients with neuromuscular disorders such as myasthenia gravis or parkinsonism since these drugs may aggravate muscle weakness because of their potential curare-like effect on the neuromuscular function.
Use of amikacin may result in overgrowth of nonsusceptible organisms. If this occurs, appropriate therapy should be instituted.
General: Prescribing amikacin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patients and increases the risk of the development of drug-resistant bacteria.
Use in Children: Use amikacin with caution and in reduced dose in premature and full-term neonates because of the renal immaturity of these patients and resulting prolongation of serum half-life of the drug.
Use in Elderly: Special care is required when using amikacin in the elderly in whom renal function may be impaired, as old age appears to be an independent risk factor for ototoxicity and nephrotoxicity. Measure blood levels frequently and give the drug for no longer than is essential.
Safety for treatment periods longer than 14 days has not been established.
Patients treated with parenteral aminoglycosides should be under close clinical observation. Amikacin sulfate injection is potentially nephrotoxic, ototoxic and neurotoxic. Avoid concurrent use of other ototoxic or nephrotoxic agents because of the potential additive effects.
Patients with preexisting tinnitus, vertigo, subclinical high-frequency hearing loss, or renal impairment and patients who are receiving high doses and/or prolonged therapy with aminoglycosides or who have received prior ototoxic drugs are especially susceptible to ototoxicity and should be carefully observed for signs of eighth cranial nerve damage during aminoglycoside therapy.
Assess kidney function by the usual methods prior to starting therapy and daily during the course of treatment. If signs of renal irritation appear, increase hydration. A reduction in dosage may be recommended if other evidence or renal dysfunction occurs such as decreased creatinine clearance, decreased urine specific gravity, and increased BUN, creatinine or oliguria. Stop the treatment if azotemia increases or if a progressive decrease in urinary output occurs.
Amikacin should be used with caution in patients with neuromuscular disorders such as myasthenia gravis or parkinsonism since these drugs may aggravate muscle weakness because of their potential curare-like effect on the neuromuscular function.
Use of amikacin may result in overgrowth of nonsusceptible organisms. If this occurs, appropriate therapy should be instituted.
General: Prescribing amikacin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patients and increases the risk of the development of drug-resistant bacteria.
Use in Children: Use amikacin with caution and in reduced dose in premature and full-term neonates because of the renal immaturity of these patients and resulting prolongation of serum half-life of the drug.
Use in Elderly: Special care is required when using amikacin in the elderly in whom renal function may be impaired, as old age appears to be an independent risk factor for ototoxicity and nephrotoxicity. Measure blood levels frequently and give the drug for no longer than is essential.
Use In Pregnancy & Lactation
Pregnancy: (Pregnancy Category D) Aminoglycosides can cause fetal harm when administered to pregnant women, but potential benefits from use of the drugs may be acceptable in certain conditions despite possible risks to the fetus. Aminoglycosides should be used during pregnancy only in life-threatening situations or severe infections for which safer drugs cannot be used or are ineffective.
Lactation: It is not known whether amikacin is excreted in human milk. Since many drugs are excreted in human milk and because of potential serious adverse reactions from amikacin in breastfeeding infants, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the drug to the mother.
Lactation: It is not known whether amikacin is excreted in human milk. Since many drugs are excreted in human milk and because of potential serious adverse reactions from amikacin in breastfeeding infants, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the drug to the mother.
Adverse Reactions
All aminoglycosides have the potential to induce auditory, vestibular, and renal toxicity and neuromuscular blockade. They occur more frequently in patients with present or past history of renal impairment, of treatment with other ototoxic or nephrotoxic drugs, and in patients treated for longer periods and/or with higher doses than recommended.
Neurotoxicity-ototoxicity: Toxic effects on the eighth cranial nerve can result in hearing loss, loss of balance or both. Amikacin primarily affects auditory function. Cochlear damage includes high frequency deafness and usually occurs before clinical hearing loss can be detected.
Neurotoxicity-Neuromuscular Blockage: Acute muscular paralysis and apnea can occur after treatment with aminoglycosides.
Nephrotoxicity: Elevated serum creatinine, albuminuria, presence of casts, red and white blood cells in the urine, azotemia, and oliguria have been reported. Renal function changes are usually reversible when the drug is discontinued.
Others: Rarely, skin rash, drug fever, headache, paresthesia, tremor, nausea and vomiting, eosinophilia, arthralgia, anemia, hypotension, and hypomagnesemia.
Neurotoxicity-ototoxicity: Toxic effects on the eighth cranial nerve can result in hearing loss, loss of balance or both. Amikacin primarily affects auditory function. Cochlear damage includes high frequency deafness and usually occurs before clinical hearing loss can be detected.
Neurotoxicity-Neuromuscular Blockage: Acute muscular paralysis and apnea can occur after treatment with aminoglycosides.
Nephrotoxicity: Elevated serum creatinine, albuminuria, presence of casts, red and white blood cells in the urine, azotemia, and oliguria have been reported. Renal function changes are usually reversible when the drug is discontinued.
Others: Rarely, skin rash, drug fever, headache, paresthesia, tremor, nausea and vomiting, eosinophilia, arthralgia, anemia, hypotension, and hypomagnesemia.
Drug Interactions
Neurotoxic, Ototoxic or Nephrotoxic Drugs: Avoid concurrent and/or sequential use with other drugs with similar toxic potential (e.g., other aminoglycosides, acyclovir, amphotericin B, bacitracin, capreomycin, cephalosporins, colistin, cisplatin, methoxyflurane, polymyxin B, vancomycin), if possible. In addition, do not give amikacin concurrently with ethacrynic acid, furosemide, urea, or mannitol because of the possibility of an increased risk of ototoxicity due to additive effects of altered serum and tissue concentrations of the antibiotics. Keep in mind the possibility that dimenhydrinate and other anti-emetics may mask symptoms of vestibular ototoxicity.
General Anesthetics and Neuromuscular Blocking Agents: Concurrent use of an aminoglycoside with general anesthetics of neuromuscular blocking agents (e.g., succinylcholine, tubocurarine) may potentiate neuromuscular blockade and cause respiratory paralysis. Use with caution in patients receiving such agents and observe signs of respiratory depression.
Neomycin: Oral neomycin may potentiate the effects of oral anticoagulants. Monitor prothrombin times in patients receiving concomitant oral aminoglycoside and oral anticoagulant therapy and adjust the dose of the anticoagulant as required.
Anti-infective Agents: In vitro studies indicate that the antibacterial activity of aminoglycosides and beta-lactam antibiotics or vancomycin may be additive or synergistic against some organisms including enterococci and P. aeruginosa. In vitro studies also indicate that aminoglycosides and extended-spectrum penicillins also exert a synergistic bactericidal effect against Enterobacteriaceae.
General Anesthetics and Neuromuscular Blocking Agents: Concurrent use of an aminoglycoside with general anesthetics of neuromuscular blocking agents (e.g., succinylcholine, tubocurarine) may potentiate neuromuscular blockade and cause respiratory paralysis. Use with caution in patients receiving such agents and observe signs of respiratory depression.
Neomycin: Oral neomycin may potentiate the effects of oral anticoagulants. Monitor prothrombin times in patients receiving concomitant oral aminoglycoside and oral anticoagulant therapy and adjust the dose of the anticoagulant as required.
Anti-infective Agents: In vitro studies indicate that the antibacterial activity of aminoglycosides and beta-lactam antibiotics or vancomycin may be additive or synergistic against some organisms including enterococci and P. aeruginosa. In vitro studies also indicate that aminoglycosides and extended-spectrum penicillins also exert a synergistic bactericidal effect against Enterobacteriaceae.
Caution For Usage
Preparation of solution for IV infusion: Add the contents of a 100, 250 or 500 mg ampule to 100 or 200 mL of sterile diluent such as Normal Saline or any of the compatible solutions listed as follows.
Adults: The solution is administered over a 30 to 60 minute period. The total daily dose should not exceed 15 mg/kg/day and may be given as a single dose or in 2 or 3 equally divided doses at equally divided intervals.
Children: The amount of fluid used will depend on the amount ordered for the patient. It should be a sufficient amount to infuse amikacin over a 30 to 60 minute period. Infants should receive a 1 to 2 hour infusion.
Inspect visually for particulate matter and discoloration prior to administration.
Do not premix amikacin with other drugs. It should be administered separately according to the recommended dose and route.
Discard unused portion after opening the ampule.
Compatibility, Storage and Stability: Amikacin is stable in 24 hours at room temperature at concentrations of 0.25 and 5 mg/mL in the following solutions: 5% Dextrose Injection, 5% Dextrose and 0.2% Sodium Chloride Injection, 5% Dextrose and 0.45% Sodium Chloride Injection, 0.9% Sodium Chloride Injection, Lactated Ringer's Injection, Normosol M in 5% Dextrose Injection, Normosol R in 5% Dextrose Injection.
Cutting Instruction: Without using any file: hold the ampule body in an upright position with one hand.
Place the right or left index finger on the one-color dot.
Apply thumb pressure on the bulb opposite the one-color dot.
Snap-break away from the body.
Discard unused portion after opening the ampule.
Adults: The solution is administered over a 30 to 60 minute period. The total daily dose should not exceed 15 mg/kg/day and may be given as a single dose or in 2 or 3 equally divided doses at equally divided intervals.
Children: The amount of fluid used will depend on the amount ordered for the patient. It should be a sufficient amount to infuse amikacin over a 30 to 60 minute period. Infants should receive a 1 to 2 hour infusion.
Inspect visually for particulate matter and discoloration prior to administration.
Do not premix amikacin with other drugs. It should be administered separately according to the recommended dose and route.
Discard unused portion after opening the ampule.
Compatibility, Storage and Stability: Amikacin is stable in 24 hours at room temperature at concentrations of 0.25 and 5 mg/mL in the following solutions: 5% Dextrose Injection, 5% Dextrose and 0.2% Sodium Chloride Injection, 5% Dextrose and 0.45% Sodium Chloride Injection, 0.9% Sodium Chloride Injection, Lactated Ringer's Injection, Normosol M in 5% Dextrose Injection, Normosol R in 5% Dextrose Injection.
Cutting Instruction: Without using any file: hold the ampule body in an upright position with one hand.
Place the right or left index finger on the one-color dot.
Apply thumb pressure on the bulb opposite the one-color dot.
Snap-break away from the body.
Discard unused portion after opening the ampule.
Storage
Store at temperatures not exceeding 30°C.
Action
Pharmacology: Pharmacodynamics: Amikacin is a semisynthetic aminoglycoside antibiotic derived from kanamycin. The addition of the side chain renders it resistant to degradation by most aminoglycoside-modifying enzymes. It binds irreversibly to the 30S subunit of the bacterial ribosome, blocking protein synthesis by inhibiting the movement of peptidyl-tRNA associated with translocation as well as increasing the frequency of misreading of the genetic code owing to incorrect codon-anticodon interaction. This leads to cell death.
Pharmacokinetics: Peak plasma concentrations of 17-25 mcg/mL are attained within 45 minutes to 2 hours after a single 500 mg intramuscular (IM) dose in adults with normal renal function. Average plasma concentration after 10 hours is 2.1 mcg/mL. When the same dose is administered by intravenous (IV) infusion over 1 hour, average peak plasma concentration of the drug is 38 mcg/mL immediately after the infusion, 5.5 mcg/mL at 4 hours, and 1.3 mcg/mL at 8 hours.
After usual dosages of amikacin, therapeutic concentrations of the drug are achieved in bone, heart, gallbladder, and lung tissue. Amikacin is also well distributed into bile, sputum, bronchial secretions, and interstitial, pleural, and synovial fluids. It crosses the placenta and can be detected in the fetus. Due to its low lipid solubility it is expected that the amount of amikacin in breast milk is insignificant.
The plasma elimination half-life of amikacin is usually 2-3 hours in adults with normal renal function and is reported to range from 30-86 hours in adults with severe renal impairment. In full terms infants 7 days or older and low-birth weight infants 1-3 days old, the plasma elimination half-life is 4-5 hours and 7-8 hours, respectively. In adults with normal renal function, 94-98% of a single IM or IV dose of amikacin is excreted unchanged by glomerular filtration within 24 hours.
Pharmacokinetics: Peak plasma concentrations of 17-25 mcg/mL are attained within 45 minutes to 2 hours after a single 500 mg intramuscular (IM) dose in adults with normal renal function. Average plasma concentration after 10 hours is 2.1 mcg/mL. When the same dose is administered by intravenous (IV) infusion over 1 hour, average peak plasma concentration of the drug is 38 mcg/mL immediately after the infusion, 5.5 mcg/mL at 4 hours, and 1.3 mcg/mL at 8 hours.
After usual dosages of amikacin, therapeutic concentrations of the drug are achieved in bone, heart, gallbladder, and lung tissue. Amikacin is also well distributed into bile, sputum, bronchial secretions, and interstitial, pleural, and synovial fluids. It crosses the placenta and can be detected in the fetus. Due to its low lipid solubility it is expected that the amount of amikacin in breast milk is insignificant.
The plasma elimination half-life of amikacin is usually 2-3 hours in adults with normal renal function and is reported to range from 30-86 hours in adults with severe renal impairment. In full terms infants 7 days or older and low-birth weight infants 1-3 days old, the plasma elimination half-life is 4-5 hours and 7-8 hours, respectively. In adults with normal renal function, 94-98% of a single IM or IV dose of amikacin is excreted unchanged by glomerular filtration within 24 hours.
MedsGo Class
Aminoglycosides
Please sign in so that we can notify you about a reply